Recipharm is pleased to announce that the results of a new study with erdosteine in "Long COVID-19" treatment are now available.
The study involved 38 COVID-19 post-discharged patients, divided into two groups: one taking erdosteine and one as control arm.
The study demonstrates that patients taking erdosteine 300 mg twice daily experience a significant greater improvement in respiratory symptoms and quality of life, compared to control arm. These outcomes confirm that erdosteine can be an effective treatment against persistent COVID-19 symptoms and can avoid the complications of Long COVID-19. Click here to access the new publication.
Recipharm is pleased to announce that the results of the study with Erdosteine as add-on treatment for COVID-19 patients are now available.
The clinical study involved 20 patients affected by COVID-19 with severe respiratory failure, hospitalized in one of the major COVID-19 centres of Milan, in Lombardy, the Italian region most affected by SARS-CoV-2.
The study indicates that patients taking Erdosteine after hospital discharge benefits significant improvements in health-related quality of life parameters (HRQoL) and dyspnea. This study is one of the first to report HRQoL details in patients with COVID-19. Click here to access the publication.